<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814268</url>
  </required_header>
  <id_info>
    <org_study_id>CLOPI_L_02452</org_study_id>
    <nct_id>NCT00814268</nct_id>
  </id_info>
  <brief_title>COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke</brief_title>
  <acronym>COMPRESS</acronym>
  <official_title>COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
        -  Comparison of efficacy of the combination therapy (clopidogrel plus aspirin) and the&#xD;
           aspirin alone (main comparison) to prevent any recurrent ischemic lesion .&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Comparison of Modified Rankin scale (mRS) scores;&#xD;
&#xD;
        -  Comparison of the Incidence of all kinds of stroke and vascular death;&#xD;
&#xD;
        -  Comparison of the Incidence of bleeding episodes (major and minor) and symptomatic&#xD;
           intracerebral hemorrhages during the follow-up period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with new ischemic lesions after the onset of acute atherothrombotic stroke</measure>
    <time_frame>Within 30 days following the onset of acute atherothrombotic stroke</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of Modified Rankin Scale (mRS) scores</measure>
    <time_frame>Day 30 after the onset of acute atherothrombotic stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with non-fatal stroke, myocardial infarction (MI) or cardiovascular death (composite endpoint, first-ever)</measure>
    <time_frame>Within 30 days following the onset of acute atherothrombotic stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with stroke (all kinds)</measure>
    <time_frame>Within 30 days following the onset of acute atherothrombotic stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with bleeding episode (major or minor)</measure>
    <time_frame>Within 30 days following the onset of acute atherothrombotic stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with symptomatic intracerebral hemorrhage (ICH)</measure>
    <time_frame>Within 30 days following the onset of acute atherothrombotic stroke</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">358</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Aspirin + Clopidogrel for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of Aspirin + Clopidogrel placebo for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>75mg tablet, oral administration once daily</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>PlavixÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel placebo</intervention_name>
    <description>Matching tablet, oral administration once daily</description>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>100mg tablet, oral administration once daily</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ischemic stroke diagnosed within 48 hours from symptom onset;&#xD;
&#xD;
          -  Cerebral ischemic lesion observed on diffusion-weighted magnetic resonance imaging&#xD;
             (DWI MRI);&#xD;
&#xD;
          -  Relevant atherothrombotic lesions on magnetic resonance angiography (MRA) or computed&#xD;
             tomography angiography (CTA);&#xD;
&#xD;
          -  Study drug administration within 48 hours from symptom onset;&#xD;
&#xD;
          -  mRS score is 0-2 before the stroke.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidences of other relevant brain lesions such as Intracerebral hemorrhage (ICH) or&#xD;
             brain tumor;&#xD;
&#xD;
          -  Suspicious of stroke due to small-vessel occlusion;&#xD;
&#xD;
          -  Stroke due to cardioembolism;&#xD;
&#xD;
          -  Clinical necessity of conventional angiography or intervention before the end of&#xD;
             study;&#xD;
&#xD;
          -  Past history of ICH;&#xD;
&#xD;
          -  Bleeding diathesis or coagulopathy;&#xD;
&#xD;
          -  Chronic anemia (Hb&lt;8.0) or thrombocytopenia (PLT&lt;100K);&#xD;
&#xD;
          -  Chronic liver disease (AST&gt; 100 or ALT&gt;100);&#xD;
&#xD;
          -  Any other clinically relevant serious disease, including renal failure ( creatinine&#xD;
             clearance&lt;30mL/min);&#xD;
&#xD;
          -  Allergy to Aspirin or clopidogrel;&#xD;
&#xD;
          -  Subjected to intervention or surgical treatments within 3 months;&#xD;
&#xD;
          -  Thrombolysis performed with rt-PA or UK after the stroke;&#xD;
&#xD;
          -  Participation in another clinical study within the previous 30 days;&#xD;
&#xD;
          -  Suspicious of poor drug compliance and requirements of the protocol;&#xD;
&#xD;
          -  Females who are pregnant, breast-feeding, or childbearing potential and not using&#xD;
             medically acceptable and effective contraception.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyang Rim Kim</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2008</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

